TWI706937B - 製備蛋白質去乙醯酶抑制劑之方法 - Google Patents

製備蛋白質去乙醯酶抑制劑之方法 Download PDF

Info

Publication number
TWI706937B
TWI706937B TW105118213A TW105118213A TWI706937B TW I706937 B TWI706937 B TW I706937B TW 105118213 A TW105118213 A TW 105118213A TW 105118213 A TW105118213 A TW 105118213A TW I706937 B TWI706937 B TW I706937B
Authority
TW
Taiwan
Prior art keywords
compound
acid
reacting
preparing
specific embodiment
Prior art date
Application number
TW105118213A
Other languages
English (en)
Chinese (zh)
Other versions
TW201718517A (zh
Inventor
法薩尼 賽迪
杜瑟 約翰Ｈ 凡
Original Assignee
美商艾斯特隆製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商艾斯特隆製藥公司 filed Critical 美商艾斯特隆製藥公司
Publication of TW201718517A publication Critical patent/TW201718517A/zh
Application granted granted Critical
Publication of TWI706937B publication Critical patent/TWI706937B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
TW105118213A 2015-06-08 2016-06-08 製備蛋白質去乙醯酶抑制劑之方法 TWI706937B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562172624P 2015-06-08 2015-06-08
US62/172,624 2015-06-08

Publications (2)

Publication Number Publication Date
TW201718517A TW201718517A (zh) 2017-06-01
TWI706937B true TWI706937B (zh) 2020-10-11

Family

ID=56264043

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105118213A TWI706937B (zh) 2015-06-08 2016-06-08 製備蛋白質去乙醯酶抑制劑之方法

Country Status (11)

Country Link
US (1) US10144714B2 (OSRAM)
EP (1) EP3303304B1 (OSRAM)
JP (1) JP6873053B2 (OSRAM)
CN (1) CN107922352B (OSRAM)
AR (1) AR105812A1 (OSRAM)
AU (2) AU2016276573A1 (OSRAM)
CA (1) CA2988594C (OSRAM)
ES (1) ES2769255T3 (OSRAM)
MX (1) MX369349B (OSRAM)
TW (1) TWI706937B (OSRAM)
WO (1) WO2016200930A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102933558B (zh) 2010-01-22 2016-03-16 埃斯泰隆制药公司 作为蛋白质去乙酰化酶抑制剂的反向酰胺化合物及其使用方法
WO2013158984A1 (en) 2012-04-19 2013-10-24 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
EP3303306B1 (en) 2015-06-08 2020-02-12 Acetylon Pharmaceuticals, Inc. Crystalline forms of a histone deacetylase inhibitor
CA2988594C (en) 2015-06-08 2023-08-15 Acetylon Pharmaceuticals, Inc. Methods of making protein deacetylase inhibitors
EP3468559B1 (en) * 2016-06-09 2023-11-22 Dana Farber Cancer Institute, Inc. Methods of use and pharmaceutical combinations of hdac inhibitors with bet inhibitors
JP7100018B2 (ja) 2016-08-08 2022-07-12 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストンデアセチラーゼ６阻害剤及びｃｄ２０阻害抗体の薬学的組み合わせならびにその使用
US11497746B2 (en) 2016-11-23 2022-11-15 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (PD-L1) inhibitor and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054099A1 (en) * 2013-10-08 2015-04-16 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
WO2001070675A2 (en) 2000-03-24 2001-09-27 Methylgene, Inc. Inhibitors of histone deacetylase
WO2002074298A1 (en) 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Il-6 production inhibitors
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
BR0213791A (pt) 2001-11-01 2004-12-07 Janssen Pharmaceutica Nv Derivados de amida como inibidores de glicogênio sintase quinase 3-beta
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7381825B2 (en) 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2531661C (en) 2003-07-07 2013-03-12 Georgetown University Histone deacetylase inhibitors and methods of use thereof
US8227636B2 (en) 2004-04-05 2012-07-24 Merck Hdac Research, Llc Histone deacetylase inhibitor prodrugs
CN101495116A (zh) 2005-03-22 2009-07-29 哈佛大学校长及研究员协会 蛋白降解病症的治疗
EP1940805A4 (en) 2005-08-26 2009-11-11 Methylgene Inc BENZODIAZEPIN AND BENZOPIPERAZINANALOGA AS INHIBITORS OF HISTONDEACETYLASE
JP5441416B2 (ja) 2006-02-14 2014-03-12 プレジデント アンド フェロウズ オブ ハーバード カレッジ 二官能性ヒストンデアセチラーゼインヒビター
CN101484156B (zh) 2006-05-03 2015-11-25 哈佛大学校长及研究员协会 组蛋白脱乙酰基酶和微管蛋白脱乙酰基酶抑制剂
WO2007144341A1 (en) 2006-06-12 2007-12-21 Vrije Universiteit Brussel Differentiation of rat liver epithelial cells into hepatocyte-like cells
ES2288802B1 (es) 2006-07-07 2008-12-16 Universidad De Granada Nuevos derivados de ftalimida como inhibidores de las histonas desacetilasas.
WO2008033746A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
EP2255818B1 (en) 2008-02-19 2018-08-22 Earnest Medicine Co., Ltd. Oral or enteral composition useful for recovery of physical functions
RU2515611C2 (ru) 2008-07-23 2014-05-20 Президент Энд Феллоуз Оф Гарвард Колледж Ингибиторы деацетилазы и их применение
WO2010131922A2 (en) 2009-05-15 2010-11-18 Korea Research Institute Of Chemical Technology Amide compound, preparation method thereof and pharmaceutical composition comprising same
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
US8551984B2 (en) * 2009-12-17 2013-10-08 Merck Sharp & Dohme Corp. Aminopyrimidines as SYK inhibitors
US20130040998A1 (en) 2010-01-08 2013-02-14 Dana-Farber Cancer Institute, Inc. Fluorinated hdac inhibitors and uses thereof
CN102933558B (zh) 2010-01-22 2016-03-16 埃斯泰隆制药公司 作为蛋白质去乙酰化酶抑制剂的反向酰胺化合物及其使用方法
AU2011255281A1 (en) 2010-05-21 2013-01-10 Sloan-Kettering Institute For Cancer Research Selective HDAC inhibitors
WO2012018499A2 (en) 2010-08-05 2012-02-09 Acetylon Pharmaceuticals Specific regulation of cytokine levels by hdac6 inhibitors
NZ710405A (en) 2010-11-16 2017-04-28 Acetylon Pharmaceuticals Inc Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
EP2734500A4 (en) 2011-07-20 2015-04-08 Gen Hospital Corp SELECTIVE HISTONDEACETYLASE-6 INHIBITORS FOR THE TREATMENT OF BONE DISORDERS
EP2760843B1 (en) * 2011-09-26 2016-03-02 Bristol-Myers Squibb Company Selective nr2b antagonists
JP5724851B2 (ja) * 2011-11-30 2015-05-27 東レ株式会社 Ｎ−（ヨードフェニル）ピリミジニルアミン誘導体の製造方法
WO2013158984A1 (en) 2012-04-19 2013-10-24 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
HK1213471A1 (zh) 2012-10-12 2016-07-08 The Trustees Of The University Of Pennsylvania 作為蛋白脫乙酰基酶抑制劑的嘧啶羥基酰胺化合物及其使用方法
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
JP2016511237A (ja) 2013-02-01 2016-04-14 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 選択的ｈｄａｃ３阻害剤
US9139583B2 (en) 2013-02-01 2015-09-22 Acetylon Pharmaceuticals, Inc. Selective HDAC3 inhibitors
WO2014197471A1 (en) 2013-06-03 2014-12-11 Acetylon Pharmaceuticals, Inc. Histone deacetylase ( hdac) biomarkers in multiple myeloma
JP2016531163A (ja) 2013-09-20 2016-10-06 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｈｄａｃ６阻害物質を用いた、異常なリンパ球の機能に起因する疾患の治療
EP3055299B1 (en) 2013-10-10 2021-01-06 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
EP3054953B1 (en) 2013-10-10 2020-07-01 Acetylon Pharmaceuticals, Inc. Hdac inhibitors in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma
JP2016536354A (ja) 2013-10-10 2016-11-24 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 非ホジキンリンパ腫を治療するための、ｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との組み合わせ
EP3054939A4 (en) 2013-10-11 2017-12-13 Acetylon Pharmaceuticals, Inc. Combinations of histone deactylase inhibitors and immunomodulatory drugs
US10660890B2 (en) 2013-10-24 2020-05-26 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) Treatment of polycystic diseases with an HDAC6 inhibitor
KR20160092018A (ko) 2013-12-03 2016-08-03 에이스틸론 파마수티컬스 인코포레이티드 히스톤 탈아세틸화효소 저해제 및 면역조절 약물의 조합
JP7017309B2 (ja) 2013-12-20 2022-02-08 アセチロン ファーマシューティカルズ インコーポレイテッド 多発性骨髄腫におけるヒストン脱アセチル化酵素６（ｈｄａｃ６）バイオマーカー
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
US20150359794A1 (en) 2014-06-13 2015-12-17 Buck Institute For Research On Aging Impairment of the large ribosomal subunit protein rpl24 by depletion or acetylation
AU2015288060A1 (en) 2014-07-07 2017-02-09 Acetylon Pharmaceuticals, Inc. Treatment of leukemia with histone deacetylase inhibitors
EP3204006A4 (en) 2014-10-08 2018-04-04 Regenacy Pharmaceuticals, LLC Induction of gata2 by hdac1 and hdac2 inhibitors
WO2016090230A1 (en) 2014-12-05 2016-06-09 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds for treating peripheral neuropathy
AU2015356779A1 (en) 2014-12-05 2017-07-13 University of Modena and Reggio Emilia Combinations of histone deacetylase inhibitors and bendamustine for use in the treatment of lymphoma
US9790180B2 (en) 2014-12-12 2017-10-17 Regenacy Pharmaceuticals, Llc Piperidine derivatives as HDAC1/2 inhibitors
US20160339022A1 (en) 2015-04-17 2016-11-24 Acetylon Pharmaceuticals Inc. Treatment of neuroblastoma with histone deacetylase inhibitors
US10272084B2 (en) 2015-06-01 2019-04-30 Regenacy Pharmaceuticals, Llc Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy
CA2988594C (en) 2015-06-08 2023-08-15 Acetylon Pharmaceuticals, Inc. Methods of making protein deacetylase inhibitors
EP3303306B1 (en) 2015-06-08 2020-02-12 Acetylon Pharmaceuticals, Inc. Crystalline forms of a histone deacetylase inhibitor
JP7100018B2 (ja) 2016-08-08 2022-07-12 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストンデアセチラーゼ６阻害剤及びｃｄ２０阻害抗体の薬学的組み合わせならびにその使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054099A1 (en) * 2013-10-08 2015-04-16 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors

Also Published As

Publication number Publication date
MX2017015900A (es) 2018-11-09
TW201718517A (zh) 2017-06-01
WO2016200930A1 (en) 2016-12-15
ES2769255T3 (es) 2020-06-25
AU2020267299A1 (en) 2020-12-10
AU2020267299B2 (en) 2022-07-07
MX369349B (es) 2019-11-06
AU2016276573A1 (en) 2018-01-04
CN107922352A (zh) 2018-04-17
AR105812A1 (es) 2017-11-15
CA2988594C (en) 2023-08-15
US10144714B2 (en) 2018-12-04
WO2016200930A9 (en) 2017-02-23
JP6873053B2 (ja) 2021-05-19
EP3303304A1 (en) 2018-04-11
CA2988594A1 (en) 2016-12-15
CN107922352B (zh) 2021-08-06
US20160355486A1 (en) 2016-12-08
EP3303304B1 (en) 2019-11-20
JP2018518486A (ja) 2018-07-12

Similar Documents

Publication Publication Date Title
TWI706937B (zh) 製備蛋白質去乙醯酶抑制劑之方法
WO2017221189A1 (en) An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof
KR102266680B1 (ko) 벨리노스테트의 다형태 및 이의 제조 방법
WO2014020555A2 (en) An improved process for the preparation of dabigatran etexilate mesylate
CN110691771A (zh) 顺式-对位取代的环己基氨基腈盐及其制备方法
WO2013065063A1 (en) Anhydrous form of dasatinib, process for its preparation and its use
TW201718516A (zh) 組蛋白去乙醯酶抑制劑之晶形
CN117897387A (zh) Glp-1受体激动剂中间体的制备方法
US20070203176A1 (en) Crystalline forms of dolasetron base and processes for preparation thereof
WO2014096373A1 (en) Process for prepararing n-(2-(7-methoxy-1-naphthalenyl)ethyl) acetamide and solid forms thereof
US20240010632A1 (en) Solid state forms of erdafitinib salts and processes for preparation of erdafitinib
US20150315164A1 (en) Process for preparing amorphous cabazitaxel
JP7492997B2 (ja) オラパリブの製造方法
WO2015104602A2 (en) A process for the preparation of anagliptin and its intermediates thereof
JP5234856B2 (ja) Ｎｐｙｙ５受容体拮抗作用を有する化合物の結晶
CN105121417B (zh) 经取代噻唑基乙酸三乙胺盐的结晶型
JP3884063B2 (ja) セフカペンピボキシルのメタンスルホン酸塩
JP2025517548A (ja) ４－置換２－オキサゾリジノンの調製プロセス
WO2022034427A1 (en) An improved process for the preparation of 4-oxoisotretinoin
JP2010526126A (ja) バルサルタンの製造方法
JPH09328473A (ja) ３，４−ジヒドロカルボスチリルの製造方法